Ridge Biotechnologies

About Ridge Biotechnologies

Ridge Bio is focused on catalyzing the next generation of precision medicines through AI-driven enzyme and targeted drug design. Their mission is to build better therapeutics using proprietary machine learning models and massive cell-free datasets to address biotechnology's most challenging problems, ultimately creating safer and more effective medicines for patients.

Products & Services

NativeLink:Enzymes for precision conjugation to modify proteins and peptides site-specifically, enabling the creation of homogeneous antibody-drug conjugates (ADCs), AOCs, radiopharmaceuticals, and other conjugates with stable linkages to expand therapeutic indices.

ProTrigger:Precision linkers for targeted therapy that conditionally activate or release payloads in target tissues, reducing off-tumor toxicity and unlocking new targets for ADCs by triggering in the tumor microenvironment.

CatalyticMedicines:Highly specific enzyme-based therapeutics with differentiated mechanisms of action to address hard-to-reach or difficult drug targets, developed with select partners to meet unmet clinical needs.

Specialties

AI-driven enzyme design Targeted drug delivery systems Precision conjugation for therapeutics Antibody-drug conjugates (ADCs) Protease-cleavable linker design Enzyme-based therapeutics Bioconjugation chemistry Precision oncology Cell-free systems

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 25000000 MR: - FA: $25 Million FAN: 25000000	D: 2025-09-09 FD: 2025-09-09	2 investors

Seed Latest

2025-09-09

$25.0M

2 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

W

Weston Kightlinger

CEO and Co-founder

LinkedIn (Pro only)

K

Keith Loebner

Director & Founding Investor

LinkedIn (Pro only)

C

Carolyn Bertozzi

SAB, Bioconjugation Chemistry

LinkedIn (Pro only)

M

Michael Jewett

Academic Co-founder & SAB Chair, Cell-free Systems

S

Sangeeta Bhatia

SAB, Precision Oncology

G

Gabe Kwong

SAB, Proteases and Linkers

View 6 more team members with Pro

Unlock Full Team Directory

Recent News